Mpex pockets $32M in second venture round
San Diego-based Mpex Pharmaceuticals has raised $32 million in its second round of venture capital. The round was led by SV Life Sciences. The biotech's most advanced candidate is an aerosol antibacterial being developed to treat patients with cystic fibrosis and those with other serious respiratory infections. "This capital will enable us to advance our first two candidates through preclinical and early clinical development, as well as attract and support future R&D partnerships," said Mpex President and CEO Bill Gerhart.
- read this press release for more
ALSO: Germany's Avontec has raised $18 million in its second round. Release
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
